Hims & Hers Health stock outlook: Seller pressure builds after FTC lawsuit

Traders Union
All News
Stocks
Hims & Hers drops 4.26% today

Highlights

Hims & Hers Health is facing a Federal Trade Commission lawsuit over alleged privacy and billing practices, raising regulatory and reputational risk.
Hagens Berman has launched an investigation into potential federal securities law violations and inadequate internal controls at Hims & Hers Health.
Shares of Hims & Hers Health dropped 4.26% to $27.39, with technical signals indicating strong selling pressure and a high-probability move toward the $25.78 to $29 range.

Regulatory lawsuits and investigations heighten legal risks and shake sentiment

Hims & Hers Health recently became the subject of a Federal Trade Commission lawsuit over alleged privacy and billing practices. This regulatory action introduces considerable uncertainty and reputational risk for the company, directly impacting investor sentiment and perceived reliability. The development has also prompted Hagens Berman to initiate an investigation into possible violations of federal securities laws and inadequate internal controls, according to Globenewswire. Together, these events intensify legal and operational concerns around the stock.

Oversold signals deepen as momentum and resistance strengthen to downside

Technically, HIMS is trading below the MA-20 at $28.21, MA-50 at $29.55, and MA-200 at $29.08, with the Ichimoku Kijun at $28.39 acting as immediate resistance. Momentum indicators continue to signal weakness: MACD and ADX both point to sustained selling pressure; RSI stands at 28.1, Stochastic RSI and CCI are both oversold, and Bull/Bear Power confirms seller dominance in intraday trading. The Awesome Oscillator also reflects a sell signal, aligning with the negative momentum observed throughout the session.

Bearish continuation likely unless price breaks key resistance

In the short term, the outlook for HIMS remains bearish, with a high probability of further downside movement. The expected volatility band is likely to be between $25.78 and $29 in the coming sessions. An upward scenario would require a decisive break above $28.39, while a close below support at $25.78 may open the way for additional losses. Baseline expectations see price oscillating within this wide sideways range.

Anton Kharitonov, expert at Traders Union, sees continued downside risk for Hims & Hers Health as regulatory headwinds amplify negative technical signals. He notes that the FTC lawsuit and additional legal investigations have damaged investor confidence and magnified governance concerns. Price action below all major moving averages and persistent selling momentum confirm a bearish setup. "With both sentiment and technicals negative, I remain defensive on HIMS — upside is unlikely unless the $28.39 resistance is retaken decisively."

Earlier, analysts noted that Hims & Hers Health was exhibiting persistent downside risks driven by technical weakness. The addition of regulatory and legal uncertainties now amplifies the bearish outlook, with traders advised to monitor for a decisive move below $25.78 as a signal for potential further losses.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.